ESMO 2024 Recap

The ESMO 2024 Congress held in Barcelona showcased several significant advancements in oncology. Here are some of the top articles and discussions from the event: Read more HERE

1. Destiny-Breast12 Study: This study highlighted the effectiveness of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in HER2-positive metastatic breast cancer patients with brain metastases. It demonstrated a 12-month progression-free survival (PFS) rate of 61.6%, indicating promising outcomes for this challenging patient population.  

2. Pembrolizumab for Triple-Negative Breast Cancer: The phase 3 KEYNOTE-522 trial results showed that neoadjuvant pembrolizumab combined with chemotherapy significantly improved overall survival in early-stage triple-negative breast cancer compared to placebo.

3. Lenvatinib and Pembrolizumab Combination: The combination of lenvatinib and pembrolizumab demonstrated nearly 90% PFS in patients with advanced thymic tumors, emphasizing its potential in treating rare cancers.

4. Belzutifan in Clear Cell RCC: Results from the LITESPARK-005 trial showed that belzutifan significantly improved PFS compared to everolimus in advanced renal cell carcinoma, reinforcing its role as a treatment option post PD-(L)1 inhibitor therapy【81†source】.

5. AI Applications in Oncology: Discussions at ESMO 2024 also focused on the increasing role of artificial intelligence in oncology, particularly in personalizing patient care and enhancing treatment outcomes【83†source】.

These highlights reflect ongoing innovation in cancer treatment and research, focusing on improving survival rates and patient care. For more detailed insights, you can check the full articles on the respective websites:

• Targeted Oncology (https://www.targetedonc.com)

• GeneOnline News (https://www.geneonline.com)

• CRA Insights (https://www.crai.com/insights-events/publications/esmo-2024-review-improving-patient-survival-through-innovations-in-oncology/)

Here are some video highlights and discussions related to ESMO 2024:

1. DESTINY-Breast12 Study Discussion: This video features a panel discussion on the key studies presented at ESMO 2024, focusing on the DESTINY-Breast12 study, which highlighted the efficacy of fam-trastuzumab deruxtecan-nxki (T-DXd) in HER2-positive metastatic breast cancer patients with brain metastases. Watch it here: https://www.vumedi.com/video/esmo-2024-summary-mbc-panel-discussion-on-key-studies-destiny-breast12-capitello-290-and-icarus-brea/

   
   

2. Neoadjuvant Pembrolizumab in Early-Stage TNBC: A discussion on the phase 3 KEYNOTE-522 trial, which showed that neoadjuvant pembrolizumab combined with chemotherapy significantly improved overall survival in early-stage triple-negative breast cancer. More details can be found in this video on https://ecancer.org/en/video/12017-tnbc-neoadjuvant-pembrolizumab-plus-chemo-followed-by-adjuvant-pembrolizumab-shows-improvement-in-os-compared-to-neoadjuvant-chemo-alone

   
   

3. Lenvatinib and Pembrolizumab for Thymic Tumors: This video discusses the promising results of the combination of lenvatinib and pembrolizumab for advanced thymic tumors, showcasing nearly a 90% progression-free survival rate​. https://www.targetedonc.com/view/lenvatinib-pembrolizumab-combo-shows-promise-in-thymic-epithelial-tumors

   
   

4. ICARUS-BREAST01 Trial Insights: A video summary highlights the promising efficacy of the novel therapy patritumab deruxtecan (HER3-DXd) in patients with advanced HR+/HER2- breast cancer​. https://oncoxchange.org/preview/video/esmo-2024-dr-cristina-saura-key-esmo-findings-on-breast-cancer-trials-breastfeeding-safety

   
   

5. Olanzapine for Nausea and Vomiting in Breast Cancer: An analysis presented at ESMO 2024 discusses using olanzapine alongside traditional antiemetics to reduce nausea and vomiting in metastatic breast cancer patients.